{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:39Z","timestamp":1792197639129,"version":"4.4.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"DOI":"10.1038\/s41574-026-01312-2","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:02:45Z","timestamp":1792166565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u03b2-cells in type 1 diabetes mellitus: findings from human pancreas studies"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2453-5889","authenticated-orcid":false,"given":"Decio L.","family":"Eizirik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-4938","authenticated-orcid":false,"given":"Eugenia","family":"Martin-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Roca-Rivada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-8573","authenticated-orcid":false,"given":"Xiaoyan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik, D. L., Pasquali, L. & Cnop, M. Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat. Rev. Endocrinol. 16, 349\u2013362 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1312_CR2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio, L. A., Evans-Molina, C. & Oram, R. A. Type 1 diabetes. Lancet 391, 2449\u20132462 (2018).","journal-title":"Lancet"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43856-024-00478-y","volume":"4","author":"JL Felton","year":"2024","unstructured":"Felton, J. L. et al. Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review. Commun. Med. 4, 66 (2024).","journal-title":"Commun. Med."},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11892-025-01595-1","volume":"25","author":"A Khine","year":"2025","unstructured":"Khine, A. & Quandt, Z. From prediction to prevention: the intricacies of islet autoantibodies in type 1 diabetes. Curr. Diab Rep. 25, 38 (2025).","journal-title":"Curr. Diab Rep."},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2337\/diabetes.48.3.460","volume":"48","author":"AG Ziegler","year":"1999","unstructured":"Ziegler, A. G., Hummel, M., Schenker, M. & Bonifacio, E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48, 460\u2013468 (1999).","journal-title":"Diabetes"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1210\/jc.2003-031887","volume":"89","author":"JM Barker","year":"2004","unstructured":"Barker, J. M. et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J. Clin. Endocrinol. Metab. 89, 3896\u20133902 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1312_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00125-025-06573-6","volume":"69","author":"S Kuusela","year":"2025","unstructured":"Kuusela, S. et al. Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative. Diabetologia 69, 93\u2013102 (2025).","journal-title":"Diabetologia"},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel, R. A. et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964\u20131974 (2015).","journal-title":"Diabetes Care"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2213-8587(24)00239-0","volume":"12","author":"LM Jacobsen","year":"2024","unstructured":"Jacobsen, L. M., Atkinson, M. A., Sosenko, J. M. & Gitelman, S. E. Time to reframe the disease staging system for type 1 diabetes. Lancet Diabetes Endocrinol. 12, 924\u2013933 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1312_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI199728","volume":"135","author":"DL Eizirik","year":"2025","unstructured":"Eizirik, D. L. & Zimath, P. L. Diabetes research enters the biobank era: searching for the truth in a deep well. J. Clin. Invest. 135, e199728 (2025).","journal-title":"J. Clin. Invest."},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-025-06579-0","volume":"69","author":"FS Wong","year":"2026","unstructured":"Wong, F. S., Pearson, J. A. & Wen, L. Is the NOD mouse a good model for type 1 diabetes? Diabetologia 69, 3\u201319 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"Haller, M. J. et al. ISPAD Clinical Practice Consensus Guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm. Res. Paediatr. 97, 529\u2013545 (2024).","journal-title":"Horm. Res. Paediatr."},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2337\/dci25-0066","volume":"49","author":"C Mathieu","year":"2026","unstructured":"Mathieu, C. et al. Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab. Diabetes Care 49, 365\u2013374 (2026).","journal-title":"Diabetes Care"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/dmrr.2316","volume":"28","author":"M Campbell-Thompson","year":"2012","unstructured":"Campbell-Thompson, M. et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab. Res. Rev. 28, 608\u2013617 (2012).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2337\/db19-0058","volume":"68","author":"KH Kaestner","year":"2019","unstructured":"Kaestner, K. H., Powers, A. C., Naji, A., Consortium, H. & Atkinson, M. A. NIH initiative to improve understanding of the pancreas, islet, and autoimmunity in type 1 diabetes: the Human Pancreas Analysis Program (HPAP). Diabetes 68, 1394\u20131402 (2019).","journal-title":"Diabetes"},{"key":"1312_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI195267","volume":"135","author":"T Dos Santos","year":"2025","unstructured":"Dos Santos, T. et al. Altered immune and metabolic molecular pathways drive islet cell dysfunction in human type 1 diabetes. J. Clin. Invest. 135, e195267 (2025).","journal-title":"J. Clin. Invest."},{"key":"1312_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cmet.2024.09.001","volume":"37","author":"JD Ewald","year":"2025","unstructured":"Ewald, J. D. et al. HumanIslets.com: improving accessibility, integration, and usability of human research islet data. Cell Metab. 37, 7\u201311 (2025).","journal-title":"Cell Metab."},{"key":"1312_CR18","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1530\/JOE-21-0358","volume":"252","author":"SJ Richardson","year":"2021","unstructured":"Richardson, S. J. & Pugliese, A. 100 Years of insulin: pancreas pathology in type 1 diabetes: an evolving story. J. Endocrinol. 252, R41\u2013R57 (2021).","journal-title":"J. Endocrinol."},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00125-026-06731-4","volume":"69","author":"SY Chen","year":"2026","unstructured":"Chen, S. Y. et al. From pancreas and islet resources to diabetes insights. Diabetologia 69, 1741\u20131758 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00125-025-06578-1","volume":"69","author":"RH Stimson","year":"2026","unstructured":"Stimson, R. H. et al. Persistent C-peptide secretion is associated with favourable CGM metrics in adults with type 1 diabetes. Diabetologia 69, 59\u201368 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66198-6","volume":"16","author":"A Rippa","year":"2025","unstructured":"Rippa, A. et al. 3D imaging of human pancreas suggests islet size and endocrine composition influence their loss in type 1 diabetes. Nat. Commun. 16, 11379 (2025).","journal-title":"Nat. Commun."},{"key":"1312_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adz2251","volume":"11","author":"K Murrall","year":"2025","unstructured":"Murrall, K. et al. Small things matter: lack of extraislet \u03b2 cells in type 1 diabetes. Sci. Adv. 11, eadz2251 (2025).","journal-title":"Sci. Adv."},{"key":"1312_CR23","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/db25-0326","volume":"74","author":"DM Drotar","year":"2025","unstructured":"Drotar, D. M. et al. Loss of insulin-positive cell clusters precedes the decrease in islet frequency and \u03b2-cell area in type 1 diabetes. Diabetes 74, 2008\u20132015 (2025).","journal-title":"Diabetes"},{"key":"1312_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11892-014-0552-7","volume":"14","author":"M Bogdani","year":"2014","unstructured":"Bogdani, M. et al. Extracellular matrix components in the pathogenesis of type 1 diabetes. Curr. Diab Rep. 14, 552 (2014).","journal-title":"Curr. Diab Rep."},{"key":"1312_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cmet.2019.01.003","volume":"29","author":"YJ Wang","year":"2019","unstructured":"Wang, Y. J. et al. Multiplexed in situ imaging mass cytometry analysis of the human endocrine pancreas and immune system in type 1 diabetes. Cell Metab. 29, 769\u2013783 (2019).","journal-title":"Cell Metab."},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2337\/db09-0685","volume":"58","author":"DA Cunha","year":"2009","unstructured":"Cunha, D. A. et al. Glucagon-like peptide-1 agonists protect pancreatic \u03b2-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58, 2851\u20132862 (2009).","journal-title":"Diabetes"},{"key":"1312_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady8048","volume":"11","author":"C Cui","year":"2025","unstructured":"Cui, C. et al. \u03b1 Cells use both PC1\/3 and PC2 to process proglucagon peptides and control insulin secretion. Sci. Adv. 11, eady8048 (2025).","journal-title":"Sci. Adv."},{"key":"1312_CR28","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s00125-025-06634-w","volume":"69","author":"RE Dewhurst-Trigg","year":"2026","unstructured":"Dewhurst-Trigg, R. E. et al. Characterisation of human pancreatic mesenchymal stromal cells in type 1 diabetes. Diabetologia 69, 966\u2013986 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","volume":"36","author":"ML Colli","year":"2018","unstructured":"Colli, M. L. et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction. EBioMedicine 36, 367\u2013375 (2018).","journal-title":"EBioMedicine"},{"key":"1312_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16327-0","volume":"11","author":"ML Colli","year":"2020","unstructured":"Colli, M. L. et al. An integrated multi-omics approach identifies the landscape of interferon-\u03b1-mediated responses of human pancreatic beta cells. Nat. Commun. 11, 2584 (2020).","journal-title":"Nat. Commun."},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2337\/db07-1260","volume":"57","author":"CJ Wang","year":"2008","unstructured":"Wang, C. J. et al. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes 57, 1861\u20131869 (2008).","journal-title":"Diabetes"},{"key":"1312_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00125-024-06313-2","volume":"68","author":"C Rao","year":"2025","unstructured":"Rao, C. et al. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes. Diabetologia 68, 382\u2013396 (2025).","journal-title":"Diabetologia"},{"key":"1312_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109538","volume":"36","author":"AV Parent","year":"2021","unstructured":"Parent, A. V. et al. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep. 36, 109538 (2021).","journal-title":"Cell Rep."},{"key":"1312_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aed0496","volume":"12","author":"J Lehrstrand","year":"2026","unstructured":"Lehrstrand, J. et al. 3D imaging of an entire pancreas shows inverse proportions of extra-islet versus islet-associated \u03b2 cells in late-onset type 1 diabetes. Sci. Adv. 12, eaed0496 (2026).","journal-title":"Sci. Adv."},{"key":"1312_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.cmet.2018.11.014","volume":"29","author":"N Damond","year":"2019","unstructured":"Damond, N. et al. A map of human type 1 diabetes progression by imaging mass cytometry. Cell Metab. 29, 755\u2013768 (2019).","journal-title":"Cell Metab."},{"key":"1312_CR36","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.2337\/db25-0457","volume":"74","author":"B Watts","year":"2025","unstructured":"Watts, B. et al. \u03b2-Cell neogenesis from the pancreatic ductal epithelium revealed dynamically by long-term intravital imaging. Diabetes 74, 2016\u20132022 (2025).","journal-title":"Diabetes"},{"key":"1312_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.2869","volume":"11","author":"C Giesen","year":"2014","unstructured":"Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417\u2013422 (2014).","journal-title":"Nat. Methods"},{"key":"1312_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s42255-022-00531-x","volume":"4","author":"M Fasolino","year":"2022","unstructured":"Fasolino, M. et al. Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes. Nat. Metab. 4, 284\u2013299 (2022).","journal-title":"Nat. Metab."},{"key":"1312_CR39","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00125-012-2604-3","volume":"55","author":"I Marhfour","year":"2012","unstructured":"Marhfour, I. et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 55, 2417\u20132420 (2012).","journal-title":"Diabetologia"},{"key":"1312_CR40","doi-asserted-by":"publisher","first-page":"211ra156","DOI":"10.1126\/scitranslmed.3006534","volume":"5","author":"F Engin","year":"2013","unstructured":"Engin, F. et al. Restoration of the unfolded protein response in pancreatic \u03b2 cells protects mice against type 1 diabetes. Sci. Transl. Med. 5, 211ra156 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1312_CR41","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2337\/db23-0130","volume":"72","author":"RM Elgamal","year":"2023","unstructured":"Elgamal, R. M. et al. An integrated map of cell type-specific gene expression in pancreatic islets. Diabetes 72, 1719\u20131728 (2023).","journal-title":"Diabetes"},{"key":"1312_CR42","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s42255-026-01559-z","volume":"8","author":"N Steenbuck","year":"2026","unstructured":"Steenbuck, N. et al. Imaging mass cytometry reveals functional and immunological changes during type 1 diabetes progression in human pancreata. Nat. Metab. 8, 1603\u20131620 (2026).","journal-title":"Nat. Metab."},{"key":"1312_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.cmet.2017.08.013","volume":"26","author":"C Wasserfall","year":"2017","unstructured":"Wasserfall, C. et al. Persistence of pancreatic insulin mRNA expression and proinsulin protein in type 1 diabetes pancreata. Cell Metab. 26, 568\u2013575 (2017).","journal-title":"Cell Metab."},{"key":"1312_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116174","volume":"44","author":"MK Huber","year":"2025","unstructured":"Huber, M. K. et al. Beta cell dysfunction occurs independently of insulitis in type 1 diabetes pathogenesis. Cell Rep. 44, 116174 (2025).","journal-title":"Cell Rep."},{"key":"1312_CR45","doi-asserted-by":"publisher","first-page":"eaed3762","DOI":"10.1126\/scitranslmed.aed3762","volume":"18","author":"F Engin","year":"2026","unstructured":"Engin, F. & Eizirik, D. L. Beyond bystanders: how \u03b2 cell stress shapes the autoimmune response in T1D. Sci. Transl. Med. 18, eaed3762 (2026).","journal-title":"Sci. Transl. Med."},{"key":"1312_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2337\/db25-0473","volume":"75","author":"M Oshima","year":"2026","unstructured":"Oshima, M. et al. Killing of human \u03b2-cells by CD8+ T cells triggers inflammatory paracrine signaling and neighboring \u03b2-cell dysfunction. Diabetes 75, 124\u2013132 (2026).","journal-title":"Diabetes"},{"key":"1312_CR47","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2019.01.021","volume":"29","author":"PJ Thompson","year":"2019","unstructured":"Thompson, P. J. et al. Targeted elimination of senescent beta cells prevents type 1 diabetes. Cell Metab. 29, 1045\u20131060 (2019).","journal-title":"Cell Metab."},{"key":"1312_CR48","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00125-019-05047-w","volume":"63","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen, L. M. et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia 63, 588\u2013596 (2020).","journal-title":"Diabetologia"},{"key":"1312_CR49","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00125-020-05115-6","volume":"63","author":"P Leete","year":"2020","unstructured":"Leete, P. et al. Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia 63, 1258\u20131267 (2020).","journal-title":"Diabetologia"},{"key":"1312_CR50","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","volume":"19","author":"MJ Redondo","year":"2023","unstructured":"Redondo, M. J. & Morgan, N. G. Heterogeneity and endotypes in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 19, 542\u2013554 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1312_CR51","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00125-025-06462-y","volume":"68","author":"C Evans-Molina","year":"2025","unstructured":"Evans-Molina, C. et al. The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment \u2014 2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia 68, 1859\u20131878 (2025).","journal-title":"Diabetologia"},{"key":"1312_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady0080","volume":"11","author":"R Melton","year":"2025","unstructured":"Melton, R. et al. Single-cell multiome and spatial profiling reveals pancreas cell type-specific gene regulatory programs of type 1 diabetes progression. Sci. Adv. 11, eady0080 (2025).","journal-title":"Sci. Adv."},{"key":"1312_CR53","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00125-024-06106-7","volume":"67","author":"A Coomans de Brach\u00e8ne","year":"2024","unstructured":"Coomans de Brach\u00e8ne, A. et al. Interferons are key cytokines acting on pancreatic islets in type 1 diabetes. Diabetologia 67, 908\u2013927 (2024).","journal-title":"Diabetologia"},{"key":"1312_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103469","volume":"156","author":"X Yi","year":"2025","unstructured":"Yi, X. et al. Transcriptomics of autoimmune diseases identifies FGFR1 as a target for pancreatic \u03b2-cell protection. J. Autoimmun. 156, 103469 (2025).","journal-title":"J. Autoimmun."},{"key":"1312_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70026","volume":"16","author":"X Yi","year":"2024","unstructured":"Yi, X. & Eizirik, D. L. \u03b2-Cell gene expression stress signatures in types 1 and 2 diabetes. J. Diabetes 16, e70026 (2024).","journal-title":"J. Diabetes"},{"key":"1312_CR56","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2337\/diab.40.11.1418","volume":"40","author":"BA Margulis","year":"1991","unstructured":"Margulis, B. A., Sandler, S., Eizirik, D. L., Welsh, N. & Welsh, M. Liposomal delivery of purified heat shock protein hsp70 into rat pancreatic islets as protection against interleukin 1 \u03b2-induced impaired \u03b2-cell function. Diabetes 40, 1418\u20131422 (1991).","journal-title":"Diabetes"},{"key":"1312_CR57","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2337\/db18-0686","volume":"68","author":"MA Russell","year":"2019","unstructured":"Russell, M. A. et al. HLA class II antigen processing and presentation pathway components demonstrated by transcriptome and protein analyses of islet \u03b2-cells from donors with type 1 diabetes. Diabetes 68, 988\u20131001 (2019).","journal-title":"Diabetes"},{"key":"1312_CR58","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00125-026-06746-x","volume":"69","author":"N Erdem","year":"2026","unstructured":"Erdem, N. et al. Human pancreatic ductal cells from non-diabetic donors function as non-professional antigen-presenting cells upon inflammatory cytokine exposure. Diabetologia 69, 2323\u20132337 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adx7770","volume":"18","author":"LE Wagner","year":"2026","unstructured":"Wagner, L. E. et al. A mitochondrial ROS-dependent antiviral response promotes \u03b2 cell resilience and is diminished in donors with type 1 diabetes. Sci. Transl. Med. 18, eadx7770 (2026).","journal-title":"Sci. Transl. Med."},{"key":"1312_CR60","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41588-019-0524-6","volume":"51","author":"M Ramos-Rodriguez","year":"2019","unstructured":"Ramos-Rodriguez, M. et al. The impact of proinflammatory cytokines on the \u03b2-cell regulatory landscape provides insights into the genetics of type 1 diabetes. Nat. Genet. 51, 1588\u20131595 (2019).","journal-title":"Nat. Genet."},{"key":"1312_CR61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41574-023-00826-3","volume":"19","author":"DL Eizirik","year":"2023","unstructured":"Eizirik, D. L., Szymczak, F. & Mallone, R. Why does the immune system destroy pancreatic \u03b2-cells but not \u03b1-cells in type 1 diabetes? Nat. Rev. Endocrinol. 19, 425\u2013434 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1312_CR62","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41418-026-01669-x","volume":"33","author":"X Yi","year":"2026","unstructured":"Yi, X. et al. Differential immune- and apoptosis-related gene signatures in pancreatic alpha and beta cells contribute to their fate in type 1 diabetes. Cell Death Differ. 33, 1706\u20131717 (2026).","journal-title":"Cell Death Differ."},{"key":"1312_CR63","doi-asserted-by":"publisher","unstructured":"Martin-Vazquez, E. et al. From bats to humans: uncovering ISG15 as a new resistance factor in type 1 diabetes. Preprint at bioRxiv. https:\/\/doi.org\/10.64898\/2026.04.02.713107 (2026).","DOI":"10.64898\/2026.04.02.713107"},{"key":"1312_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59626-0","volume":"16","author":"GJ Golden","year":"2025","unstructured":"Golden, G. J. et al. Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset. Nat. Commun. 16, 4621 (2025).","journal-title":"Nat. Commun."},{"key":"1312_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adz0472","volume":"10","author":"M Abedi","year":"2025","unstructured":"Abedi, M. et al. Joint profiling of gene expression and chromatin accessibility in pancreatic lymph nodes and spleens in human type 1 diabetes. Sci. Immunol. 10, eadz0472 (2025).","journal-title":"Sci. Immunol."},{"key":"1312_CR66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00125-002-1017-0","volume":"46","author":"AK Cardozo","year":"2003","unstructured":"Cardozo, A. K. et al. IL-1\u03b2 and IFN-\u03b3 induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46, 255\u2013266 (2003).","journal-title":"Diabetologia"},{"key":"1312_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","volume":"159","author":"BO Roep","year":"2010","unstructured":"Roep, B. O. et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin. Exp. Immunol. 159, 338\u2013343 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"1312_CR68","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","volume":"602","author":"SV Gearty","year":"2022","unstructured":"Gearty, S. V. et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature 602, 156\u2013161 (2022).","journal-title":"Nature"},{"key":"1312_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.192755","volume":"11","author":"Y Wu","year":"2026","unstructured":"Wu, Y. et al. Anti-CD3 mAb treatment reshapes infiltrating T and \u03b2 cells in the islets in autoimmune diabetes. JCI Insight 11, e192755 (2026).","journal-title":"JCI Insight"},{"key":"1312_CR70","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2337\/dc26-0795","volume":"49","author":"MA Thelin","year":"2026","unstructured":"Thelin, M. A. et al. Type 1 diabetes driven by residual recipient T cells after hematopoietic cell transplantation: a case report. Diabetes Care 49, 1694\u20131699 (2026).","journal-title":"Diabetes Care"},{"key":"1312_CR71","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00125-025-06382-x","volume":"68","author":"EK Sims","year":"2025","unstructured":"Sims, E. K. et al. IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia 68, 993\u20131004 (2025).","journal-title":"Diabetologia"},{"key":"1312_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2026.117144","volume":"45","author":"MA Medina-Serpas","year":"2026","unstructured":"Medina-Serpas, M. A. et al. Spatial transcriptomics from pancreas and local draining lymph node tissue reveals a lymphotoxin-\u03b2 signature in human type 1 diabetes. Cell Rep. 45, 117144 (2026).","journal-title":"Cell Rep."},{"key":"1312_CR73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162123","volume":"132","author":"K Warncke","year":"2022","unstructured":"Warncke, K. et al. Elevations in blood glucose before and after the appearance of islet autoantibodies in children. J. Clin. Invest. 132, e162123 (2022).","journal-title":"J. Clin. Invest."},{"key":"1312_CR74","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel, M. et al. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N. Engl. J. Med. 389, 2140\u20132150 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1312_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105734","volume":"117","author":"F Syed","year":"2025","unstructured":"Syed, F. et al. Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice. EBioMedicine 117, 105734 (2025).","journal-title":"EBioMedicine"},{"key":"1312_CR76","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00125-025-06576-3","volume":"69","author":"W Aniagyei","year":"2026","unstructured":"Aniagyei, W. et al. Heterogeneity in clinically diagnosed type 1 diabetes: characterising a unique cohort with maintained C-peptide secretion in Ghana. Diabetologia 69, 308\u2013320 (2026).","journal-title":"Diabetologia"},{"key":"1312_CR77","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/dmrr.460","volume":"20","author":"R Lupi","year":"2004","unstructured":"Lupi, R. et al. Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes Metab. Res. Rev. 20, 246\u2013251 (2004).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"1312_CR78","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.2337\/db14-1911","volume":"64","author":"L Krogvold","year":"2015","unstructured":"Krogvold, L. et al. Function of isolated pancreatic islets from patients at onset of type 1 diabetes: insulin secretion can be restored after some days in a nondiabetogenic environment in vitro: results from the DiViD Study. Diabetes 64, 2506\u20132512 (2015).","journal-title":"Diabetes"},{"key":"1312_CR79","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads2905","volume":"11","author":"M Suleiman","year":"2025","unstructured":"Suleiman, M. et al. Functional recovery of islet \u03b2 cells in human type 2 diabetes: transcriptome signatures unveil therapeutic approaches. Sci. Adv. 11, eads2905 (2025).","journal-title":"Sci. Adv."},{"key":"1312_CR80","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00125-017-4536-4","volume":"61","author":"A Coomans de Brachene","year":"2018","unstructured":"Coomans de Brachene, A. et al. IFN-\u03b1 induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia 61, 636\u2013640 (2018).","journal-title":"Diabetologia"},{"key":"1312_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dom.13388","volume":"20","author":"MI Alvelos","year":"2018","unstructured":"Alvelos, M. I., Juan-Mateu, J., Colli, M. L., Turatsinze, J. V. & Eizirik, D. L. When one becomes many \u2014 alternative splicing in \u03b2-cell function and failure. Diabetes Obes. Metab. 20, 77\u201387 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"1312_CR82","doi-asserted-by":"publisher","first-page":"624590","DOI":"10.3389\/fendo.2020.624590","volume":"11","author":"JD Piganelli","year":"2020","unstructured":"Piganelli, J. D., Mamula, M. J. & James, E. A. The role of \u03b2 cell stress and neo-epitopes in the immunopathology of type 1 diabetes. Front. Endocrinol. 11, 624590 (2020).","journal-title":"Front. Endocrinol."},{"key":"1312_CR83","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2337\/dbi21-0036","volume":"71","author":"R Mallone","year":"2022","unstructured":"Mallone, R., Halliez, C., Rui, J. & Herold, K. C. The \u03b2-cell in type 1 diabetes pathogenesis: a victim of circumstances or an instigator of tragic events? Diabetes 71, 1603\u20131610 (2022).","journal-title":"Diabetes"},{"key":"1312_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd7600","volume":"7","author":"F Szymczak","year":"2021","unstructured":"Szymczak, F., Colli, M. L., Mamula, M. J., Evans-Molina, C. & Eizirik, D. L. Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis. Sci. Adv. 7, eabd7600 (2021).","journal-title":"Sci. Adv."},{"key":"1312_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105376","volume":"25","author":"X Yi","year":"2022","unstructured":"Yi, X. et al. Mining the transcriptome of target tissues of autoimmune and degenerative pancreatic \u03b2-cell and brain diseases to discover therapies. iScience 25, 105376 (2022).","journal-title":"iScience"},{"key":"1312_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi8577","volume":"390","author":"B DeMeo","year":"2025","unstructured":"DeMeo, B. et al. Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes. Science 390, eadi8577 (2025).","journal-title":"Science"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01312-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01312-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:58Z","timestamp":1792194958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01312-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":86,"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01312-2","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"23 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.L.E. received grant support from Novo Nordisk for research on differences between pancreatic \u03b1-cells and \u03b2-cells and new approaches to protect pancreatic \u03b2-cells in type 1 diabetes mellitus, and is a member of the scientific advisory board of InSphero AG. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}